Investor presentation outlines fingerprint-sweat drug screening system
Intelligent Bio Solutions published an investor presentation outlining its fingerprint-sweat drug screening system, positioned as a rapid, non-invasive workplace testing alternative.
U.S. regulatory path centered on an FDA 510(k) submission for codeine targeted for Q4 2026, following additional-data requests in September 2025.
Plan assumes potential 510(k) clearance in H1 2027, followed by U.S. distribution buildout, faster cartridge development, expanded drug indications.
Reported FY 2026 revenue of USD 4.21 million, up 38% year over year; gross margin of 65%.
Disclosed 500+ active customer accounts across 35 countries and territories, supported by a consumables-led recurring revenue model tied to cartridge sales.
INBS•
